This STAT3-mediated enhancement of immune checkpoint expression contributes to tumor immune evasion and may help explain the limited efficacy of immune checkpoint blockade therapy in end-stage cancer patients, particularly those suffering from cancer cachexia (134, 135). Here, STAT3 is linked to cancer.